Intellia Therapeutics, Inc. (NTLA)

NASDAQ: NTLA · Real-Time Price · USD

12.81

-0.30 (-2.29%)

At close: Mar 24, 2026, 4:00 PM EDT

13.17

+0.36 (2.81%)

After-hours: Mar 24, 2026, 7:53 PM EDT

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Development of Gene Editing-Based Therapies	67.67M	57.88M	36.28M	52.12M	33.05M
Development of Gene Editing-Based Therapies Growth	16.92%	59.55%	-30.40%	57.69%	-43.01%
Total	67.67M	57.88M	36.28M	52.12M	33.05M
Total Growth	16.92%	59.55%	-30.40%	57.69%	-43.01%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
United States	67.67M	57.88M	36.28M	52.12M	33.05M
United States Growth	16.92%	59.55%	-30.40%	57.69%	-43.01%
Total	67.67M	57.88M	36.28M	52.12M	33.05M
Total Growth	16.92%	59.55%	-30.40%	57.69%	-43.01%

Source: S&P Global Market Intelligence.